{"id":413,"date":"2018-08-28T14:08:06","date_gmt":"2018-08-28T12:08:06","guid":{"rendered":"https:\/\/biologika-register.de?page_id=413"},"modified":"2022-04-04T09:58:32","modified_gmt":"2022-04-04T07:58:32","slug":"results","status":"publish","type":"page","link":"https:\/\/biologika-register.de\/en\/rabbit\/results\/","title":{"rendered":"Results"},"content":{"rendered":"
\"\"
Scientific results are shown on posters at congresses<\/figcaption><\/figure>\n

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.<\/p>\n

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.<\/p>\n

Here, we will give a short insight into our published results: Original publications<\/a><\/p>\n

<\/h4>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Eingeschlossene Patienten: 24.086 (Stand 02. April 2026)<\/th><\/td>\n<\/tr>\n<\/thead>\n
Amgevita\u00ae (Adalimumab)<\/td>278<\/td>\n<\/tr>\n
Avtozma\u00ae (Tocilizumab)<\/td>1<\/td>\n<\/tr>\n
Benepali\u00ae (Etanercept)<\/td>1344<\/td>\n<\/tr>\n
Cimzia\u00ae (Certolizumab)<\/td>1070<\/td>\n<\/tr>\n
Enbrel\u00ae (Etanercept)<\/td>2882<\/td>\n<\/tr>\n
Erelzi\u00ae (Etanercept)<\/td>647<\/td>\n<\/tr>\n
Flixabi\u00ae (Infliximab)<\/td>10<\/td>\n<\/tr>\n
Hukyndra\u00ae (Adalimumab)<\/td>27<\/td>\n<\/tr>\n
Hulio\u00ae (Adalimumab)<\/td>330<\/td>\n<\/tr>\n
Humira\u00ae (Adalimumab)<\/td>2912<\/td>\n<\/tr>\n
Hyrimoz\u00ae (Adalimumab)<\/td>310<\/td>\n<\/tr>\n
Idacio\u00ae (Adalimumab)<\/td>77<\/td>\n<\/tr>\n
Imraldi\u00ae (Adalimumab)<\/td>264<\/td>\n<\/tr>\n
Inflectra\u2122 (Infliximab)<\/td>16<\/td>\n<\/tr>\n
Jyseleca\u00ae (Filgotinib)<\/td>211<\/td>\n<\/tr>\n
Kevzara\u00ae (Sarilumab)<\/td>251<\/td>\n<\/tr>\n
Kineret\u00ae (Anakinra)<\/td>89<\/td>\n<\/tr>\n
MabThera\u00ae (Rituximab)<\/td>1459<\/td>\n<\/tr>\n
Nepexto\u00ae (Etanercept)<\/td>131<\/td>\n<\/tr>\n
Olumiant\u00ae (Baricitinib)<\/td>570<\/td>\n<\/tr>\n
Orencia\u00ae (Abatacept)<\/td>1003<\/td>\n<\/tr>\n
Remicade\u00ae (Infliximab)<\/td>762<\/td>\n<\/tr>\n
Remsima\u00ae (Infliximab)<\/td>27<\/td>\n<\/tr>\n
Rinvoq\u00ae (Upadacitinib)<\/td>375<\/td>\n<\/tr>\n
Rixathon\u00ae (Rituximab)<\/td>20<\/td>\n<\/tr>\n
RoActemra\u00ae (Tocilizumab)<\/td>1385<\/td>\n<\/tr>\n
Ruxience\u00ae (Rituximab)<\/td>1<\/td>\n<\/tr>\n
Simponi\u00ae (Golimumab)<\/td>486<\/td>\n<\/tr>\n
Truxima\u00ae (Rituximab)<\/td>9<\/td>\n<\/tr>\n
Tyenne\u00ae (Tocilizumab)<\/td>84<\/td>\n<\/tr>\n
Xeljanz\u00ae (Tofacitinib)<\/td>406<\/td>\n<\/tr>\n
Yuflyma\u00ae (Adalimumab)<\/td>93<\/td>\n<\/tr>\n
Zessly\u00ae (Infliximab)<\/td>2<\/td>\n<\/tr>\n
Kontrollen<\/td>6554<\/td>\n<\/tr>\n
<\/td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, … mehr<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":241,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_crdt_document":"","generate_page_header":"","footnotes":""},"class_list":{"0":"post-413","1":"page","2":"type-page","3":"status-publish","5":"infinite-scroll-item"},"_links":{"self":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/comments?post=413"}],"version-history":[{"count":16,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/413\/revisions"}],"predecessor-version":[{"id":3444,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/413\/revisions\/3444"}],"up":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/241"}],"wp:attachment":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/media?parent=413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}